deltatrials
Terminated PHASE3 INTERVENTIONAL 3-arm NCT05655520

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

A Phase 3, Multicenter, Open-label Safety Study to Evaluate the Long-term Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

Sponsor: Supernus Pharmaceuticals, Inc.

Conditions Huntington's Disease
Interventions SAGE-718
Updated 15 times since 2023 Last updated: Dec 2, 2025 Started: Dec 14, 2022 Primary completion: Jan 20, 2025 Completion: Jan 20, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Internal company decision

Other terminated trials from Supernus Pharmaceuticals, Inc.

More terminations from Supernus Pharmaceuticals, Inc.

Other Huntington's Disease trials with similar outcome

Browse all Huntington's Disease trials

A PHASE3 clinical study on Huntington's Disease, this trial is terminated or withdrawn. The trial is conducted by Supernus Pharmaceuticals, Inc. and has accumulated 15 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~May 2023 · 3 months · monthly snapshot~May 2023 – ~Jul 2023 · 2 months · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 7 months · monthly snapshot

Change History

15 versions recorded

  1. Jan 2026 — Present [monthly]

    Terminated PHASE3

  2. Sep 2025 — Jan 2026 [monthly]

    Terminated PHASE3

  3. Mar 2025 — Sep 2025 [monthly]

    Terminated PHASE3

    Status: Active Not Recruiting → Terminated

  4. Feb 2025 — Mar 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Jan 2025 — Feb 2025 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

▶ Show 10 earlier versions

  1. Sep 2024 — Jan 2025 [monthly]

    Recruiting PHASE3

  2. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  3. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE3

  4. Nov 2023 — Jul 2024 [monthly]

    Recruiting PHASE3

  5. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE3

  6. Aug 2023 — Oct 2023 [monthly]

    Recruiting PHASE3

  7. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE3

  8. May 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

  9. Feb 2023 — May 2023 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  10. Jan 2023 — Feb 2023 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Dec 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Supernus Pharmaceuticals, Inc.
Data source: Supernus Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Baltimore, United States , Birmingham, United Kingdom , Birmingham, United States , Boca Raton, United States , Boston, United States , Cardiff, United Kingdom , Caulfield South, Australia , Chapel Hill, United States , Charleston, United States and 32 more locations